Your session is about to expire
← Back to Search
Dostarlimab for Pancreatic Cancer
Study Summary
This trial will test if a combination of dostarlimab, niraparib, and radiation therapy can help control metastatic pancreatic cancer.
- Pancreatic Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 18 Patients • NCT04409002Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What physical ailments is Dostarlimab generally employed to alleviate?
"Generally, dostarlimab is primarily prescribed for primary peritoneal cancer. In other cases, it can be applied to advanced mismatch repair-deficient (dmmr) endometrial cancer which has not responded to platinum-based chemotherapy and fallopian tubes cancer."
To what extent has this research study been populated by participants?
"This trial is no longer accepting participants. Initially posted on July 23rd 2020, and last updated September 7th 2022, the study has since concluded its recruitment phase. For those looking for other clinical trials related to malignant neoplasm of pancreas or Dostarlimab there are presently 704 and 115 studies respectively that are actively enrolling patients."
Are there any vacancies available in this clinical research program?
"The recruitment for this clinical trial has since concluded, with the initial posting on July 23rd 2020 and a final update on September 7th 2022. Nonetheless, there are still numerous studies recruiting patients affected by malignant neoplasm of pancreas (704) and Dostarlimab (115)."
Has Dostarlimab received regulatory endorsement from the FDA?
"Based on prior research, the safety of Dostarlimab is rated as a 2 since this Phase 2 trial includes data suggesting its security but lacks evidence for efficacy."
What prior research exists regarding Dostarlimab's efficacy?
"As of now, 115 clinical trials are underway to test the efficacy of Dostarlimab with 14 in Phase 3. Most have been set up near Washington DC and a total of 3320 sites are hosting these studies."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Average response time
- < 1 Day
Typically responds via
Most responsive sites:
- Beth Israel Deaconess Medical Center: < 24 hours
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger